FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3094844125> ?p ?o ?g. }

• W3094844125 endingPage "33" @default.
• W3094844125 startingPage "31" @default.
• W3094844125 abstract "Follicular lymphoma (FL) is considered an indolent disorder with a relatively favourable course. With modern day treatments, long remissions are often achieved both in front-line and relapsed settings. However, a subset of patients has a more aggressive course and a poorer outcome. Both, PET-CT and minimal residual disease (MRD) evaluation by PCR defines groups of patients with different prognoses. MRD measurement by NGS is being studied to predict relapse prior to diagnostic imaging in large B cell lymphoma; however, it has never been used in FL. The aim of the present study is to validate a sensitive and standardizable approach to measure liquid Biopsy MRD (LiqBio-MRD) by NGS with &gt;90% applicability and 2E-4 resolution, and to analyse its prognostic impact in FL patients. Firstly, the best source to identify genetic MRD markers was determined. Genomic DNA from paraffin embedded (FFPE) lymph node biopsies and/or cell free DNA (cfDNA) from peripheral blood (PB) was obtained from 29 FL cases at diagnosis and sequenced with a short length Ampliseq Custom Panel (Thermo-Fisher). This panel was designed to cover all coding regions of 56 lymphoma specific genes in FFPE and cfDNA samples. By applying this panel with an average depth of 700X, a total of 122 somatic mutations were detected in 37 baseline samples. 15 of these lymph node samples presented 65 mutations (average of 4 mutations per patient, rank 1-9), with a mean Variant Read Frequency (VRF) of 0.33 (0.06-0.77). On the other hand, the 21 cfDNA samples presented 71 mutations (average of 3 mutations per patient, rank 0-8), with a mean VRF of 0.21 (0.02-1.0). Notably, in 3 cases the mutations were only detected in the lymph node. Paired samples were available for 13 cases. Of the 72 somatic mutations identified in these cases, only 14 were present in both samples (Figure 1A, left). Besides the higher number of mutations in the lymph nodes, a mean decrease of 0.14 VRF was observed in cfDNA (0.21; 0.03-0.53) compared to lymph nodes (0.35; 0.09-0.76) (Figure 1A, Right). From the initial 29 FL cases, 16 had PB sequential samples available. Three patients were put under observation and the rest received an anthracycline based regimen plus R-maintenance. In treated patients, PET-CT was carried out at diagnosis and after 4 and 6 cycles of treatment. During follow-up, cfDNA was available after 4 (n=10) and 6 cycles of treatment (n=10). Median follow up was 18 months. To quantify LiqBio-MRD in the 31 follow-up samples, we defined an approach involving the sequencing of 12 NGS data points per mutation identified at diagnosis. Three of these data points were tumour sample replicates. The other 9 points were obtained from healthy control donor DNA. All LiqBio-MRD samples were sequenced with at least 100.000x and analysed applying the NGS-MRD algorithm described elsewhere (Onecha, E et al. Hematologica 2019). The mean mutation rate (noise) in controls for the studied mutations was 1.4E-5 (0 - 8E-5) below the targeted sensibility of 2E-4. The LOD was defined for every follow-up sample based on the initial amount of cfDNA used in the test. On average 39.6ng (13-66 ng) were used for cfDNA MRD monitoring. All somatic mutations were considered potential MRD markers (Figure 1B), however the degree of MRD in each follow-up sample was defined by the somatic mutation with higher VRF. MRD values were significantly lower in complete response (CR) cases compared to those with active disease (p=0.001, Figure 1C, left). Notably, MRD positivity in the interim or at the end of treatment resulted in significantly inferior PFS (median 12 months vs not reached, P = 0.09, Figure 1C, right). An extension of the cohort and clinical impact of LiqBio-MRD test will be presented at the meeting. Our results demonstrate for the first time that NGS based MRD quantification is feasible in Liquid Biopsies from FL. Despite the marked spatial genetic heterogeneity of FL, which is better identified in cfDNA, the dilution of the signal in these samples suggests the use of both; lymph node biopsies and cfDNA at diagnosis to identify all potential MRD markers. The lower degree of MRD in CR evaluations (according to the 2014 Lugano response assessment) and the existence of patients in CR with positive and negative MRD suggest the potential of our LiqBio-MRD test to prospectively identify patients with different outcome. Nevertheless, more patients and a longer follow-up are necessary to draw meaningful conclusions. Figure 1 Disclosures Heredia: Altum sequencing: Current Employment. Rufian:Altum sequencing: Current Employment. Carrillo:Altum sequencing: Current Employment. Wang:Hosea Precision Medical Technology Co., Ltd: Current Employment. Canales:Janssen: Honoraria; Karyopharm: Honoraria; Celgene: Honoraria; Takeda: Speakers Bureau; Sandoz: Honoraria; Janssen: Speakers Bureau; Novartis: Honoraria; Sandoz: Speakers Bureau; Janssen: Speakers Bureau; Takeda: Speakers Bureau; Roche: Honoraria; iQone: Honoraria; Janssen: Honoraria; Sandoz: Honoraria; Novartis: Honoraria; Roche: Honoraria; Roche: Speakers Bureau; Karyopharm: Honoraria; Gilead: Honoraria; Sandoz: Speakers Bureau; Roche: Speakers Bureau. Martinez-López:Janssen, BMS, Sanofi, Novartis, Incyte, F. Hoffmann-La Roche and Amgen: Honoraria, Other: Advisory boards; Janssen, Novartis, BMS, Incyte: Consultancy; Hosea and Altum: Membership on an entity's Board of Directors or advisory committees." @default.
• W3094844125 created "2020-11-09" @default.
• W3094844125 creator A5004401859 @default.
• W3094844125 creator A5024436174 @default.
• W3094844125 creator A5026001642 @default.
• W3094844125 creator A5034182883 @default.
• W3094844125 creator A5035233311 @default.
• W3094844125 creator A5036644670 @default.
• W3094844125 creator A5039397983 @default.
• W3094844125 creator A5042720583 @default.
• W3094844125 creator A5047288670 @default.
• W3094844125 creator A5050028537 @default.
• W3094844125 creator A5055020157 @default.
• W3094844125 creator A5056453244 @default.
• W3094844125 creator A5056493270 @default.
• W3094844125 creator A5058946643 @default.
• W3094844125 creator A5062686728 @default.
• W3094844125 creator A5067825842 @default.
• W3094844125 creator A5076514135 @default.
• W3094844125 creator A5080601782 @default.
• W3094844125 creator A5084561376 @default.
• W3094844125 date "2020-11-05" @default.
• W3094844125 modified "2023-10-18" @default.
• W3094844125 title "Minimal Residual Disease Monitoring from Liquid Biopsy By Next Generation Sequencing in Follicular Lymphoma Patients" @default.
• W3094844125 doi "https://doi.org/10.1182/blood-2020-139256" @default.
• W3094844125 hasPublicationYear "2020" @default.
• W3094844125 type Work @default.
• W3094844125 sameAs 3094844125 @default.
• W3094844125 citedByCount "2" @default.
• W3094844125 countsByYear W30948441252023 @default.
• W3094844125 crossrefType "journal-article" @default.
• W3094844125 hasAuthorship W3094844125A5004401859 @default.
• W3094844125 hasAuthorship W3094844125A5024436174 @default.
• W3094844125 hasAuthorship W3094844125A5026001642 @default.
• W3094844125 hasAuthorship W3094844125A5034182883 @default.
• W3094844125 hasAuthorship W3094844125A5035233311 @default.
• W3094844125 hasAuthorship W3094844125A5036644670 @default.
• W3094844125 hasAuthorship W3094844125A5039397983 @default.
• W3094844125 hasAuthorship W3094844125A5042720583 @default.
• W3094844125 hasAuthorship W3094844125A5047288670 @default.
• W3094844125 hasAuthorship W3094844125A5050028537 @default.
• W3094844125 hasAuthorship W3094844125A5055020157 @default.
• W3094844125 hasAuthorship W3094844125A5056453244 @default.
• W3094844125 hasAuthorship W3094844125A5056493270 @default.
• W3094844125 hasAuthorship W3094844125A5058946643 @default.
• W3094844125 hasAuthorship W3094844125A5062686728 @default.
• W3094844125 hasAuthorship W3094844125A5067825842 @default.
• W3094844125 hasAuthorship W3094844125A5076514135 @default.
• W3094844125 hasAuthorship W3094844125A5080601782 @default.
• W3094844125 hasAuthorship W3094844125A5084561376 @default.
• W3094844125 hasBestOaLocation W30948441251 @default.
• W3094844125 hasConcept C126322002 @default.
• W3094844125 hasConcept C142724271 @default.
• W3094844125 hasConcept C143998085 @default.
• W3094844125 hasConcept C2775934546 @default.
• W3094844125 hasConcept C2777058707 @default.
• W3094844125 hasConcept C2778461978 @default.
• W3094844125 hasConcept C2779338263 @default.
• W3094844125 hasConcept C2779823535 @default.
• W3094844125 hasConcept C2780849966 @default.
• W3094844125 hasConcept C71924100 @default.
• W3094844125 hasConceptScore W3094844125C126322002 @default.
• W3094844125 hasConceptScore W3094844125C142724271 @default.
• W3094844125 hasConceptScore W3094844125C143998085 @default.
• W3094844125 hasConceptScore W3094844125C2775934546 @default.
• W3094844125 hasConceptScore W3094844125C2777058707 @default.
• W3094844125 hasConceptScore W3094844125C2778461978 @default.
• W3094844125 hasConceptScore W3094844125C2779338263 @default.
• W3094844125 hasConceptScore W3094844125C2779823535 @default.
• W3094844125 hasConceptScore W3094844125C2780849966 @default.
• W3094844125 hasConceptScore W3094844125C71924100 @default.
• W3094844125 hasIssue "Supplement 1" @default.
• W3094844125 hasLocation W30948441251 @default.
• W3094844125 hasOpenAccess W3094844125 @default.
• W3094844125 hasPrimaryLocation W30948441251 @default.
• W3094844125 hasRelatedWork W1552274294 @default.
• W3094844125 hasRelatedWork W1978208370 @default.
• W3094844125 hasRelatedWork W2026358441 @default.
• W3094844125 hasRelatedWork W2052443417 @default.
• W3094844125 hasRelatedWork W2088213302 @default.
• W3094844125 hasRelatedWork W2185614907 @default.
• W3094844125 hasRelatedWork W2389996938 @default.
• W3094844125 hasRelatedWork W2411903623 @default.
• W3094844125 hasRelatedWork W4200431323 @default.
• W3094844125 hasRelatedWork W4311963332 @default.
• W3094844125 hasVolume "136" @default.
• W3094844125 isParatext "false" @default.
• W3094844125 isRetracted "false" @default.
• W3094844125 magId "3094844125" @default.
• W3094844125 workType "article" @default.